Scandinavian ChemoTech has secured CE-marked electrodes for deep-seated tumours
Following successful final tests Scandinavian ChemoTech, along with its partner in electrode technology, has developed CE-marked treatment kits for deep-seated tumours.
The Company's new treatment kits are primarily developed for the treatment of deep-seated tumours. These have now passed the important compatibility tests between the new electrodes and our TSE™ technology. These new kits are intended for use in both human and veterinary medicine.
“It feels very good to have been able to secure access to CE-marked treatment kits even for deep-seated tumours. This enables us to now begin clinical trials on these kinds of tumours, which in significant ways may change the conditions for both ChemoTech and Vetiqure.” - says Mohan Frick, CEO Scandinavian ChemoTech
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-10-2021 09:30 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
